Better CD33-targeted treatments for acute myeloid leukemia
Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders
['FUNDING_OTHER'] · FRED HUTCHINSON CANCER CENTER · NIH-11141116
Researchers are developing new CD33-targeted antibody therapies paired with a potent alpha-particle agent to help people with acute myeloid leukemia.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11141116 on ClinicalTrials.gov |
What this research studies
If you have AML, this work focuses on new antibodies that bind a different part of the CD33 protein found on leukemia cells. The team will attach a tiny but powerful radioactive particle (astatine-211) to those antibodies to deliver focused radiation directly to cancer cells. They will run lab experiments and animal studies to find the safest and most effective antibody designs and dosing that spare normal blood cells. The goal is to prepare the best approaches for testing in patients at their center.
Who could benefit from this research
Good fit: People with CD33-positive acute myeloid leukemia—particularly those with relapsed or treatment-resistant disease—would be the most likely candidates for future trials.
Not a fit: Patients whose leukemia does not express CD33 or who cannot tolerate targeted radiation approaches would be unlikely to benefit from this work.
Why it matters
Potential benefit: Could produce more effective and safer CD33-directed treatments that kill AML cells while reducing harm to normal blood cells.
How similar studies have performed: An earlier CD33 drug (gemtuzumab ozogamicin) improved outcomes for some AML patients, but many CD33-directed approaches have failed, and combining new CD33 antibodies with astatine-211 is a newer, mostly preclinical strategy.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LASZLO, GEORGE S — FRED HUTCHINSON CANCER CENTER
- Study coordinator: LASZLO, GEORGE S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.